Novo to Build Diabetes Pen Plant in Iran as Sanctions Ease

Updated on
  • Danish drugmaker to spend 70 million euros on new factory
  • Easing sanctions to boost economy and spending on healthcare

Novo Nordisk A/S, the world’s biggest maker of insulin, will build a plant to assemble its FlexPen pre-filled devices in Iran to expand in a country where millions suffer from diabetes, two months after an international accord on sanctions relief.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.